Align Technology, the maker of Invisalign aligners, announced that a more than $1.4 million judgment was issued on August 10 in its favor in a patent infringement case against Angelalign Technology's operating subsidiaries in China.
The Jinan Intermediate People's Court in China ruled that Angelalign's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system used to generate A7 and A7 Speed premolar extraction treatments infringed on Align's patent related to extraction-gap-closure technology, according to a press release dated August 11 from Align.
Furthermore, the court determined that aligner products made and sold using the technology in question infringed on Align's patent.
The court ruled that Angelalign must stop using the patented technology and cease making and selling infringing products in China, according to the press release.
On August 13, Angelalign announced it would appeal the judgment, according to Angelalign's press release.
This judgment follows other rulings in Align’s patent-enforcement actions against Angelalign.
In July 2026, the U.S. International Trade Commission (ITC) conducted an evidentiary hearing concerning five patents asserted by Align against Angel. The ITC is expected to make an initial determination regarding the merits of Align’s claims in November 2026, according to the press release.
In February 2026, the Unified Patent Court issued a preliminary injunction requiring Angelalign to stop infringing on Align's patented ClinCheck Live Update technology. The decision was upheld on appeal. Additionally, Align continues to pursue additional patent infringement actions against Angelalign affiliates in China and Europe, according to the press release.
